Shares of BioScrip Inc. (NASDAQ:BIOS) traded down 2.6% during mid-day trading on Monday . The company traded as low as $2.55 and last traded at $2.62, with a volume of 295,291 shares changing hands. The stock had previously closed at $2.69.

Separately, Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a report on Friday, June 17th.

The stock’s market capitalization is $181.58 million. The stock has a 50 day moving average of $2.63 and a 200 day moving average of $2.23.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.05. During the same period in the previous year, the business earned ($0.17) EPS. The company had revenue of $238.50 million for the quarter, compared to analysts’ expectations of $232.38 million. BioScrip’s revenue was down 2.4% compared to the same quarter last year. Equities research analysts predict that BioScrip Inc. will post ($0.20) EPS for the current year.

In other BioScrip news, Director David W. Golding bought 12,500 shares of the stock in a transaction on Friday, June 17th. The stock was purchased at an average price of $2.48 per share, with a total value of $31,000.00. Following the acquisition, the director now owns 42,500 shares of the company’s stock, valued at $105,400. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Coliseum Capital Management, L bought 4,200,000 shares of the stock in a transaction on Wednesday, June 22nd. The shares were acquired at an average cost of $2.00 per share, with a total value of $8,400,000.00. The disclosure for this purchase can be found here.

A number of hedge funds have added to or reduced their stakes in the company. Diamond Hill Capital Management Inc. raised its stake in BioScrip by 2.5% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,055,476 shares of the company’s stock worth $5,347,000 after buying an additional 74,757 shares in the last quarter. Gabelli Funds LLC raised its stake in BioScrip by 22.9% in the fourth quarter. Gabelli Funds LLC now owns 11,430,900 shares of the company’s stock worth $20,004,000 after buying an additional 2,132,060 shares in the last quarter. Finally, Gamco Investors INC. ET AL raised its stake in BioScrip by 1.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 864,850 shares of the company’s stock worth $1,513,000 after buying an additional 12,250 shares in the last quarter.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.